Redenlab CSO, Adam Vogel, will be presenting at the upcoming joint webinar with the European Reference Network for rare or low prevalence complex diseases, Neurological Diseases (ERN-RND), Neuromuscular Dieseases (ERN EURO-NMD), and European Academy of Neurology. The subject of the webinar is Speech as a biomarker in Ataxia: What can it tell us & how should we use it. Sign up here!
Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic options for...
Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination difficulties. SCA1...
Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to significant changes...
